IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Trial details
- Registry ID
- NCT05077709
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCNCT05077709 | IO Biotech | Phase 2 | Completed | 2025-11-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |